On 26 April 2023, the European Commission published its long awaited proposal to revise the EU pharmaceutical legislation.  The proposal includes a new draft Regulation, which will repeal Regulation (EC) No 726/2004, the Orphan Medicines Regulation 141/2000 and the Paediatric Regulation 1901/2006.

As expected, the draft Regulation significantly shakes up incentives available to the

The European Commission (“Commission”) intends to change the rules on regulatory data protection (“RDP”) of medicinal products.  The Commission stated in its Impact Assessment for the revised pharmaceutical legislation that it wants to strike a balance between “providing attractive incentives for innovation and supporting timely patient access to medicinal products across the EU.” 

This is the first in a series of Covington blogs about the EU’s proposals to amend the current pharmaceutical regulatory framework, which were released today (see here).  It introduces some of the key aims and themes and invites readers to read more in-depth summaries as we release them. 

The proposals have been in

Complex international pharmaceutical supply chains often separate the physical flow of product from financial flows or flows of legal title. Tune in to this episode of Covington’s Life Sciences Audiocast, where Grant Castle, Robin Blaney and Marie Doyle-Rossi, discuss how the EU and UK pharmaceutical rules seek to regulate these tax and